Type 1 diabetes mellitus following COVID-19 RNA-based vaccine

Kanako Sakurai, Daiki Narita, Naomi Saito, Takayuki Ueno, Ryota Sato, Satsuki Niitsuma, Kazuhiro Takahashi, Zenei Arihara

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)


The epidemic of coronavirus disease-2019 (COVID-19) is the major public health issue in the world. COVID-19 vaccines are one of the most effective strategies against COVID-19. Here we report a 36-year-old female patient who had thirst, polydipsia, polyuria, palpitations, loss of appetite, and fatigue 3 days after the first dose of COVID-19 RNA-based vaccines without a prior history of diabetes. Ten days after vaccination, she visited our hospital with diabetic ketoacidosis and was diagnosed with type 1 diabetes. Hyperglycemia (501 mg/dL), anion gap metabolic acidosis and ketonuria were observed. The glycated hemoglobin level was 7.0%. Islet-related autoantibodies were all negative. The glucagon tolerance test revealed attenuated secretion of insulin. Human leukocyte antigen was haplotype DRB1*0405-DQB1*0401, which was associated with type 1 diabetes in Japan. The present case suggests that COVID-19 RNA-based vaccines might trigger the onset of type 1 diabetes, even in subjects without prior histories of diabetes.

Original languageEnglish
Pages (from-to)1290-1292
Number of pages3
JournalJournal of Diabetes Investigation
Issue number7
Publication statusPublished - 2022 Jul


  • COVID-19 RNA-based vaccines
  • Ketoacidosis
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Type 1 diabetes mellitus following COVID-19 RNA-based vaccine'. Together they form a unique fingerprint.

Cite this